

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Wahlstrom Mats</u>  (Last) (First) (Middle) <u>C/O COHERUS BIOSCIENCES, INC.</u> <u>333 TWIN DOLPHIN DRIVE, SUITE 600</u>  (Street) <u>REDWOOD CITY CA 94065</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Coherus BioSciences, Inc. [ CHRS ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/17/2017</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.0001 par value	02/22/2017		j <sup>(1)</sup>		200,000	D	\$0.00	378,528	I	See Footnote <sup>(2)</sup>
Common Stock, \$0.0001 par value	02/22/2017		j <sup>(1)</sup>		109,957	A	\$0.00	109,957	I	See Footnote <sup>(3)</sup>
Common Stock, \$0.0001 par value	05/09/2017		j <sup>(4)</sup>		200,000	D	\$0.00	178,528	I	See Footnote <sup>(2)</sup>
Common Stock, \$0.0001 par value	05/09/2017		j <sup>(4)</sup>		109,957	A	\$0.00	219,914	I	See Footnote <sup>(3)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$23.8	05/17/2017		A		20,000		(5)	05/17/2027	Common Stock	20,000	\$0.00	20,000	D	

**Explanation of Responses:**

- KMG Capital Partners, LLC distributed an aggregate of 200,000 shares of common stock of the issuer to its limited and general partners for no consideration on February 22, 2017. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC.
- The shares are held by KMG Capital Partners, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by KMG Capital Partners, LLC except to the extent of his pecuniary interest therein.
- The shares are held by Leonard Capital, LLC. Mr. Wahlstrom disclaims beneficial ownership of the shares held by Leonard Capital, LLC except to the extent of his pecuniary interest therein.
- KMG Capital Partners, LLC distributed an aggregate of 200,000 shares of common stock of the issuer to its limited and general partners for no consideration on April 27, 2017. Reflects pro rata allocation of such shares distributed to Leonard Capital, LLC.
- The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

**Remarks:**

/s/ Jean-Frederic Viret, as  
Attorney-in-Fact for Mats                      05/19/2017  
Wahlstrom

\*\* Signature of Reporting Person                      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.